T2D · CVRM · 9 drugs · 2 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| Orforglipron | LLY | Oral GLP-1 agonist | Small molecule | ORAL | FILED |
| Retatrutide | LLY | GLP-1/GIP/Glucagon triple agonist | Peptide | SC | PHASE3 |
| elecoglipron | AZN | Oral GLP-1 agonist | Small molecule | ORAL | PHASE3 |
| Trulicity | LLY | GLP-1 agonist | Peptide | SC | APPROVED |
| Farxiga | AZN | SGLT2 inhibitor | Small molecule | ORAL | APPROVED |
| Jardiance | LLY | SGLT2 inhibitor | Small molecule | ORAL | APPROVED |
| Mounjaro | LLY | GLP-1/GIP dual agonist | Peptide | SC | APPROVED |
| Trajenta | LLY | DPP-4 inhibitor | Small molecule | ORAL | APPROVED |
| Januvia | MRK | DPP-4 inhibitor | Small molecule | PO | APPROVED |